Inotiv 향후 성장
Future 기준 점검 0/6
Inotiv은 연간 수입과 매출이 각각 20.6%와 5.6% 증가할 것으로 예상되고 EPS는 연간 21.5%만큼 증가할 것으로 예상됩니다.
핵심 정보
20.6%
이익 성장률
21.54%
EPS 성장률
| Life Sciences 이익 성장 | 17.5% |
| 매출 성장률 | 5.6% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 09 Feb 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.
내러티브 업데이트 • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
내러티브 업데이트 • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.내러티브 업데이트 • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
내러티브 업데이트 • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.내러티브 업데이트 • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.내러티브 업데이트 • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.내러티브 업데이트 • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.내러티브 업데이트 • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.내러티브 업데이트 • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.새로운 내러티브 • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.내러티브 업데이트 • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).내러티브 업데이트 • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.내러티브 업데이트 • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).내러티브 업데이트 • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).내러티브 업데이트 • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.분석 기사 • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...분석 기사 • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
새로운 내러티브 • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.분석 기사 • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...분석 기사 • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...분석 기사 • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...분석 기사 • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...분석 기사 • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...분석 기사 • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 9/30/2028 | 587 | N/A | 30 | N/A | 1 |
| 9/30/2027 | 558 | -63 | 11 | N/A | 2 |
| 9/30/2026 | 530 | -78 | 5 | N/A | 2 |
| 3/31/2026 | 507 | -87 | -14 | 0 | N/A |
| 12/31/2025 | 514 | -69 | -29 | -11 | N/A |
| 9/30/2025 | 513 | -69 | -27 | -10 | N/A |
| 6/30/2025 | 505 | -79 | -46 | -27 | N/A |
| 3/31/2025 | 480 | -87 | -54 | -34 | N/A |
| 12/31/2024 | 475 | -121 | -26 | -5 | N/A |
| 9/30/2024 | 491 | -108 | -29 | -7 | N/A |
| 6/30/2024 | 501 | -99 | -9 | 14 | N/A |
| 3/31/2024 | 553 | -71 | 10 | 33 | N/A |
| 12/31/2023 | 585 | -33 | 4 | 29 | N/A |
| 9/30/2023 | 572 | -105 | 0 | 28 | N/A |
| 6/30/2023 | 582 | -340 | -17 | 9 | N/A |
| 3/31/2023 | 597 | -345 | -42 | -4 | N/A |
| 12/31/2022 | 586 | -341 | -50 | -11 | N/A |
| 9/30/2022 | 548 | -337 | -42 | -5 | N/A |
| 6/30/2022 | 427 | -83 | -38 | -3 | N/A |
| 3/31/2022 | 277 | -77 | -15 | 10 | N/A |
| 12/31/2021 | 156 | -72 | -9 | 8 | N/A |
| 9/30/2021 | 90 | 11 | -2 | 11 | N/A |
| 6/30/2021 | 75 | 0 | -2 | 8 | N/A |
| 3/31/2021 | 68 | -4 | 0 | 5 | N/A |
| 12/31/2020 | 65 | -4 | -4 | 1 | N/A |
| 9/30/2020 | 60 | -5 | -5 | 1 | N/A |
| 6/30/2020 | 59 | -3 | -6 | 2 | N/A |
| 3/31/2020 | 55 | -2 | -7 | 1 | N/A |
| 12/31/2019 | 48 | -2 | N/A | 2 | N/A |
| 9/30/2019 | 44 | -1 | N/A | 2 | N/A |
| 6/30/2019 | 38 | -1 | N/A | 3 | N/A |
| 3/31/2019 | 33 | -1 | N/A | 4 | N/A |
| 12/31/2018 | 30 | 0 | N/A | 4 | N/A |
| 9/30/2018 | 26 | 0 | N/A | 3 | N/A |
| 6/30/2018 | 23 | 0 | N/A | 2 | N/A |
| 3/31/2018 | 23 | 1 | N/A | 2 | N/A |
| 12/31/2017 | 23 | 1 | N/A | 1 | N/A |
| 9/30/2017 | 24 | 1 | N/A | 1 | N/A |
| 6/30/2017 | 24 | -1 | N/A | 2 | N/A |
| 3/31/2017 | 23 | -2 | N/A | 1 | N/A |
| 12/31/2016 | 22 | -3 | N/A | 2 | N/A |
| 9/30/2016 | 20 | -3 | N/A | 1 | N/A |
| 6/30/2016 | 20 | -2 | N/A | 1 | N/A |
| 3/31/2016 | 21 | 0 | N/A | 2 | N/A |
| 12/31/2015 | 22 | 0 | N/A | 2 | N/A |
| 9/30/2015 | 23 | 1 | N/A | 2 | N/A |
| 6/30/2015 | 24 | 1 | N/A | 2 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: NOTV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: NOTV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: NOTV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: NOTV 의 수익(연간 5.6%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: NOTV 의 수익(연간 5.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: NOTV의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/14 11:48 |
| 종가 | 2026/05/14 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Inotiv, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |